Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedAdded Squamous cell carcinoma of the head and neck to the conditions and included the Genetic and Rare Diseases Information Center as a new resource.SummaryDifference0.1%

- Check27 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check56 days agoChange DetectedNo substantive additions or deletions were detected in the study details; the page content remains the same.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.4.2 is displayed on the page, indicating a minor site update. There are no observed changes to the study content, eligibility criteria, or navigation.SummaryDifference0.0%

- Check70 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0 on the page.SummaryDifference0.0%

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.